Eravacycline
- TRADE NAME: Xerava (Tetraphase Pharms Inc)
- INDICATIONS: treatment of complicated intra-abdominal infections in patients 18 years of age and older.
- CLASS: Antibiotic, Antibiotic; tetracycline
- HALF-LIFE: 20 hours
FDA APPROVAL DATE: 08/27/2018
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
PREGNANCY CATEGORY: N/A
data insufficient to inform drug-associated risk of major birth defects and miscarriages.
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.
RESPIRATORY.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric